Perioperative Activation of Disseminated Tumor Cells in Bone Marrow of Patients With Prostate Cancer

Abstract

Cytokeratin-positive cells in the bone marrow of prostate cancer patients are only prognostically relevant when detected before surgery. Because we could not identify significant genetic differences between pre- and postoperatively isolated tumor cells before manifestation of metastasis, we postulate the existence of perioperative stimuli that activate disseminated tumor cells. Patients with cytokeratin-positive cells in bone marrow before surgery may therefore benefit from adjuvant therapies.

Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing

“…Cells identified in those studies, usually from patients without distant metastases, carrying a smaller number of chromosomal aberrations [23,25,33] distinct from one another and from those in the tumor under consideration [23,33], and usually consisting of wholechromosome gains or losses [23], likely correspond to AUs. These cells may have been interpreted as genuine DTCs, thus supporting a parallel progression model of the disease.…”

Testing Radical prostatectomy in men with oligoMetastatic prostate cancer that has spread to the bone

“…There is evidence that the primary tumour can seed to distant sites and cancer cells at those end-sites can further seed the primary lesion, leading to a vicious circle of metastasis 15 ; this 'self-seeding' phenomenon is dependent on the presence of an intact primary focus 16 . Furthermore, disseminated tumour cells in men with clinically localized prostate cancer before prostatectomy confer a 5-fold increased risk of future metastases but these same cells detected after surgery do not increase such risk [17][18][19] . Collectively, these biological data suggest that an intact primary lesion drives metastatic progression.…”

Radiotherapy and inhibition of the EGF family as treatment strategies for prostate cancer: combining theragnostics with theragates

“…While there have been numerous attempts to add prognostic power from other biological features, none has proven repeatedly to be of higher predictive value than the traditional Gleason score. However, in patients treated with curative treatment, detection of DTCs in BM has shown to be a prognostic marker [63,64]. Additional therapeutic benefits might be captured if tumor dynamics from repeated DTC analysis is performed [60].…”